Consensus EyePoint, Inc.

Stocks

EYPT

US30233G2093

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 21/10/2026 BST			5-day change	1st Jan Change
0.4300 ^USD	+6.12%		-85.71%	-97.65%

09-15	EyePoint, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 07:00 AM
09-09	EyePoint, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08:00 AM

Evolution of the Average Target: EyePoint, Inc.

Evolution of the Target Price: EyePoint, Inc.

Changes in Analyst Recommendations: EyePoint, Inc.

ab389963c8bac1f.jokbbo007SK_jQFTP55m87-pfjq-6WLFvZDAY5yu8YY.4b1OIOF_uBGJunsVZ680g8_5PH_PjVSWzeelEe_IoMv37X8k2VO8Ucz1bg~6730064feb25b57f73a5fd11cef86a7c

Analysts' recommendations: EyePoint, Inc.

10-20	Ocular Therapeutix Has 75% Success Probability for Axpaxli in Wet Age-Related Macular Degeneration, UBS Says	MT
10-20	EyePoint's DME Study Readout a Catalyst After wAMD Trial Misses Endpoint, RBC Says	MT
10-20	Laidlaw Downgrades EyePoint Pharmaceuticals to Hold From Buy	MT
10-20	JPMorgan Downgrades EyePoint Pharmaceuticals to Underweight From Neutral	MT
10-20	RBC Capital Adjusts Price Target on EyePoint Pharmaceuticals to $1 From $5, Keeps Sector Perform, Speculative Risk	MT
10-20	Mizuho Downgrades EyePoint Pharmaceuticals to Neutral From Outperform, Adjusts PT to $0.50 From $39	MT
10-19	Guggenheim Downgrades EyePoint to Neutral From Buy	MT
10-19	Jefferies Downgrades EyePoint Pharmaceuticals to Hold From Buy, $1 Price Target	MT
09-02	TD Cowen Downgrades EyePoint Pharmaceuticals to Hold From Buy, Adjusts PT to $4 From $20	MT
08-18	EyePoint Faces Regulatory Uncertainty After Lugano Trial Miss, RBC Capital Markets Says	MT
08-18	Chardan Downgrades EyePoint Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $5 From $65	MT
08-18	RBC Downgrades EyePoint to Sector Perform From Outperform, Cuts Price Target to $5 From $37, Keeps Speculative Risk	MT
08-18	HC Wainwright Downgrades EyePoint Pharmaceuticals to Neutral From Buy	MT
08-17	JPMorgan Downgrades EyePoint Pharmaceuticals to Neutral From Overweight	MT
08-04	Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says	MT
07-29	Mizuho Raises Price Target on EyePoint Pharmaceuticals to $39 From $36, Keeps Outperform Rating	MT
07-16	Stifel Initiates EyePoint Pharmaceuticals at Buy With $40 Price Target	MT
07-01	Chardan Boosts Price Target on EyePoint Pharmaceuticals to $65 From $29, Keeps Buy Rating	MT
05-07	RBC Capital Adjusts EyePoint Pharmaceuticals PT to $37 From $39, Maintains Outperform Speculative-Risk Rating	MT
03-05	Chardan Raises Price Target on EyePoint Pharmaceuticals to $29 From $27, Keeps Buy Rating	MT
11-06	RBC Raises Price Target on EyePoint Pharmaceuticals to $39 From $28, Keeps Outperform, Speculative Risk	MT
15/10/25	Cooking oil, hot markets
14/08/25	Mizuho Adjusts Price Target on EyePoint Pharmaceuticals to $28 From $26, Maintains Outperform Rating	MT
17/06/25	RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target	MT
16/05/25	Mizuho Cuts Price Target on EyePoint Pharmaceuticals to $26 From $30, Keeps Outperform Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	EYEPOINT, INC.					+1,982.31%
	ELI LILLY AND COMPANY					+3.71%
	JOHNSON & JOHNSON					+7.73%
	ABBVIE INC.					-2.24%
	ROCHE HOLDING AG					-1.52%
	MERCK & CO., INC.					+6.92%
	NOVARTIS AG					-2.21%
	ASTRAZENECA PLC					+24.46%
	AMGEN INC.					-10.02%
	GILEAD SCIENCES, INC.					+2.33%
	Average					+201.15%
	Weighted average by Cap.					+3.44%